Paul M. Barr MD Associate Professor of Medicine at Wilmot Cancer Institute provides his opinion on ibrutinib in 1st line…
Michael B. Atkins at Georgetown Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology follows up on…
Michael B. Atkins at Georgetown Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology elaborates on the…
Michael B. Atkins MD at Georgetown Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology provides some…
Michael B. Atkins MD at Georgetown Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology discusses the…
Michael B. Atkins MD at Georgetown Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology discusses how…
Thomas A. Abrams Senior Physician and Assistant Professor of Medicine at Harvard Medical School explains the next steps a patient…
Thomas A. Abrams Senior Physician and Assistant Professor of Medicine at Harvard Medical School tells us his thoughts on KEYNOTE-62.…
Thomas A. Abrams, Senior Physician and Assistant Medical Professor at Harvard Medical School provides results about the APACT Study. APACT…
Dr. Thomas A. Abrams, Senior Physician and Assistant Professor of Medicine at Harvard Medical School discusses whether the POLO Trial…
Lung Cancer Video Library Mandarin – Consolidation Radiation After a Good Response to 1st Line.mp4
Lung Cancer Video Library Mandarin – Combinations of Immunotherapy Agents in Advanced NSCLC.mp4
Lung Cancer Video Library Mandarin -The Basics of Managing Immune Mediated Side Effects.mp4
Lung Cancer Video Library Mandarin – Tumor Mutation Burden Current Status.mp4
Lung Cancer Video Library Mandarin – Rapid Progression Through First Line Treatment What Next.mp4
Lung Cancer Video Library Mandarin – Immunotherapy in Stage III NSCLC PACIFIC Trial and Imfinzi.mp4 Â Â Â Â mandarin,…
Lung Cancer Video Library Mandarin – Immunotherapy Combos in Adv Squamous Non Small Cell Lung Cancer.mp4
Lung Cancer Video Library Mandarin – Immunotherapy Combos in Adv Non Squamous NSCLC.mp4
Lung Cancer Video Library Mandarin – Evolving Standards for Molecular Testing in Advanced NSCLC.mp4
Lung Cancer Video Library Mandarin – Does Immunotherapy Work with Driver Mutations like EGFR ALK.mp4
Harold A. Burstein, M.D, discusses guideline updates on integration results from TAILORx. Use of Biomarkers to Guide Decisions on Adjuvant…
Philip McCarthy MD @plmcarthymd Of Roswell Park Comprehensive Cancer Center Discusses Updates On The FORTE Trial: 3 Arm Study, Higher…
Philip McCarthy MD @plmcarthymd Of Roswell Park Comprehensive Cancer Center Discusses Smoldering Myeloma ECOG Trial: Patients With Intermediate & High…
Philip McCarthy MD @plmcarthymd Of Roswell Park Comprehensive Cancer Center Discusses IMWG Classification Of Smoldering Myeloma: Incorporates Earlier Features Of…
Thomas Yau MD, MBBS Of University of Hong Kong Discusses Nivolumab + Ipilimumab Combo Therapy In Patients with aHCC Results…
Larissa Nekhlyudov MD MPH Of Brigham & Womens Hospital/Dana-Farber Cancer Institute, Harvard Medical School Discusses Bringing Primary Physician Back Into…
Larissa Nekhlyudov MD MPH Of Brigham & Womens Hospital/Dana-Farber Cancer Institute, Harvard Medical School Discusses Need To Optimize Communication &…
Aref Al-Kali MD Of The Mayo Clinic Discusses Updates In Myeloid Disorders: How To Calculate The Blast In Myelodysplastic Syndrome,…
Aref Al-Kali MD Of The Mayo Clinic Discusses How To Use Drugs In Patients With Myeloid Disorders: Focusing On Azacitidine…
Scott Tagawa MD @drscottagawa Of Weill Cornell Medicine and NewYork-Presbyterian Discusses Some That Image Well Do Not Respond: BRCA2 Is…
Scott Tagawa MD @drscottagawa Of Weill Cornell Medicine and NewYork-Presbyterian Discusses If They Are Imaging Negative, How Are They Responding:…
Scott Tagawa MD @drscottagawa Of Weill Cornell Medicine and NewYork-Presbyterian Discusses TROPHY-u-01 Trial: A Phase II Open-Label Study Of Sacituzumab…
Scott Tagawa MD @drscottagawa Of Weill Cornell Medicine and NewYork-Presbyterian Discusses Targeting PSMA: Patients That Have At Least One Bright…
Mark Fleming MD Of US Oncology Research Discusses Treatment Sequencing For Castrate Resistant M0 Disease: Looking At 3 Drugs Enzalutamide,…
Mark Fleming MD Of US Oncology Research Discusses TITAN Trial: Many Options Including Chemo, Abiraterone, Enzalutamide, & Apalutamide All Showing…
Keith T. Flaherty, M.D. Of Array BioPharma Discusses Updated Data From Phase 3 COLUMBUS Trial: Encorafenib Was The Agent Of…
Neelima Denduluri MD @ndenduluri1 Of US Oncology Research Discusses Updates On Patient Care From ASCO: New Ways To Educate Patients…
Lowell Anthony MD Of Markey Cancer Center Discusses When Do You Prescribe Bland Vs Chemo Or Radio Embolization: Chemo Embolization…
Lowell Anthony MD Of Markey Cancer Center Discusses Inducing Embolization Syndrome When Performing infarction: Not Uncommon To Take 4-8 Weeks…
Lowell Anthony MD Of Markey Cancer Center Discusses Evaluating mTOR Inhibitor Everolimus With Embolotherapy: Objective Response Rate Of 57 We…
Joshua Allen PhD @jallenphd Of Oncoceutics, Inc. Discusses Why Does This Subset Of Patients Respond To ONC201: It Appears To…
Joshua Allen PhD @jallenphd Of Oncoceutics, Inc. Discusses Other Suitable Combinations For This Agent That Could Help More People: Which…
Joshua Allen PhD @jallenphd Of Oncoceutics, Inc. Discusses Latest Data For Patients Treated With ONC201 With H3 K27M-Mutant Glioma: Median…
Max S. Topp MD Of University Hospital of Wuerzburg Discusses Using Steroids To Mitigate Cytokine-Release Syndrome: Did Not See Any…
Max S. Topp MD Of University Hospital of Wuerzburg Discusses Mitigate Cytokine-Release Syndrome With Steroids In Practice: If Only 10Of…
Joan Brugge PhD Of Harvard Medical School Discusses The Process Of Tumor Genesis & Tumor Cells Response To Therapy: Its…
Giorgio Scagliotti MD @giorgioscaglio3 Of University of Torino Discusses Updates In The Thoracic Oncology Field: We Now Have Specific Inhibitors…
Ziad Bakouny MD @ZiadBakouny Of Dana-Farber Cancer Institute Discusses Updates On Sarcomatoid & Rhabdoid Renal Cell Carcinoma: Immune Checkpoint Inhibitors…
Debra Patt MD @dapattmd Of US Oncology Research Discusses Using A.I. & Predictive Analytics In Healthcare: Will Augment Physicians Decisions…
Debra Patt MD @dapattmd Of US Oncology Research Discusses Delivering Innovated Care In The Clinic: Innovations Made In The Clinic…
Tal Zaks MD, PhD, Chief Medical Officer at Moderna Therapeutics Discusses Questions About mRNA: Takes 50-60 Days From Biopsy To…
Tal Zaks MD, PhD, Chief Medical Officer at Moderna Therapeutics Discusses How Did The Patients Do: Out Of 13 Patients…
Tal Zaks MD, PhD, Chief Medical Officer at Moderna Therapeutics Discusses Emerging Data For Personalized Vaccine Approach: Safety Profile Was…
Geraldine O’ Sullivan Coyne, MD, discusses the Phase I Trial fo Murlentamab. Background: Membranous expression of AMHRII is found in…
Geraldine O’ Sullivan Coyne, MD, discusses the Phase I Trial of Murlentamab. Background: Membranous expression of AMHRII is found in…
Scott Koenig, of Macrogenics, discusses what it will take to gain regulatory approval. About MacroGenics, Inc. MacroGenics is a clinical-stage…
Scott Koenig, of Macrogenics, discusses achieving a better outcome for patients. About MacroGenics, Inc. MacroGenics is a clinical-stage biopharmaceutical company…
Scott Koenig discusses the data on the Phase 3 SOPHIA study. About MacroGenics, Inc. MacroGenics is a clinical-stage biopharmaceutical company…
Scott Koenig discusses the Phase 3 SOPHIA study. About MacroGenics, Inc. MacroGenics is a clinical-stage biopharmaceutical company focused on discovering…
Yousuf Zafar, MD, discusses the importance of patient care. Financial barriers to clinical trial enrollment are an area of active…
Yousuf Zafar, MD, discusses the importance of questioning the qaulity and completenesss of Data. Financial barriers to clinical trial enrollment…
Yousuf Zafar, MD, discuses the role of Real World Evidence in cancer care. Financial barriers to clinical trial enrollment are…
Dr. Mehool Patel dicusses how artificial intelligence makes an impact on decisions for both clinicians and patients alike. Background: Next…
Rod Humerickhouse discusses the importance of Minimal Residual Disease Negativity. Background: The multinational, open-label, phase 3 CLL14 trial compared fixed-duration…
Rod Humerickhouse discusses the Phase 3 CLL14 Trial. Background: The multinational, open-label, phase 3 CLL14 trial compared fixed-duration targeted VenG…
Dr. Cora Sternberg Of Weill Cornell Medicine and NewYork-Presbyterian discusses the broader implications of the SAUL study. Background: Atezo, a…
Dr. Cora Sternberg Of Weill Cornell Medicine and NewYork-Presbyterian discusses results of the SAUL study. Background: Atezo, a monoclonal antibody…
Edward B. Garon discusses what the results of the KEYNOTE-001 mean for the patient. Background: Pembrolizumab (pembro) monotherapy has demonstrated…
Edward B. Garon discusses results from KEYNOTE-001. Background: Pembrolizumab (pembro) monotherapy has demonstrated durable antitumor activity in advanced PD-L1expressing NSCLC.…
Rafael Santana-Davila MD @valdesan Of Fred Hutchinson Cancer Research Center Discusses Lurbinecedin Data At ASCO Important & Encouraging/ Want To…
Jens Hillengass MD @JHillengass Of Roswell Park Comprehensive Cancer Center Discusses Updates In Myeloma: Bispecific Antibodies & New Treatment Coming…
Jens Hillengass MD @JHillengass Of Roswell Park Comprehensive Cancer Center Discusses B-Cell Maturation Antigen (BCMA): Many Trials Using This Marker…
Josh Brody MD @joshuabrodyMD Of Icahn School of Medicine at Mount Sinai Discusses Shout-Out: Very Grateful For Everything…Maybe Not All…
Josh Brody MD @joshuabrodyMD Of Icahn School of Medicine at Mount Sinai Discusses Results Of Novel In Situ Vaccine: Vaccine…
Josh Brody MD @joshuabrodyMD Of Icahn School of Medicine at Mount Sinai Discusses New PI3K-Delta Inhibitor Umbralisib: Greater Then 50%…
Dr. Ronald Shcheff, MD, Of Weill Cornell Medicine and NewYork-Presbyterian discusses the results from KEYNOTE-001. Background: Pembrolizumab (pembro) monotherapy has…
Robert Rifkin MD Of US Oncology Research Discusses Measuring BCMA: Do Not Have To Wait For Relapse, We Know When…
Robert Rifkin MD Of US Oncology Research Discusses Trial Updates At ASCO: Approval Of Daratumumab In Combination With Revlimid Or…
Robert Rifkin MD Of US Oncology Research Discusses Isatuximab & Daratumumab: When You Add Isatuximab To Pomalidomide & Dexamethasone Outcomes…
Robert Rifkin MD Of US Oncology Research Discusses Connect MM Myeloma Disease Registry: This Is A Special Group Of Myeloma…
Michael Hall, MD Of Fox Chase Cancer Center Discusses POLO Trial: PFS Increased With Olaparib As Maintenance Therapy For BRCA+…
Michael Ciesielski, Phd @mjciesielski Of Roswell Park Comprehensive Cancer Center Discusses Latest Data On SurVaxM Vaccine: Doubled Progression Free Period,…
Dr. Joseph Tabernero, MD, discusses the safety profile for Pembrolizumab. Background: KEYNOTE062 (NCT02494583) was a randomized, active controlled study of…
Dr. Joseph Tabernero, MD, discusses the phase 3 keynote-062 study. Background: KEYNOTE062 (NCT02494583) was a randomized, active controlled study of…
Philadelphia, PA (May 17, 2019) – Oncoceutics, Inc. announced that the latest efficacy data for the use of ONC201 in…
Shirish Gadgeel MD @umrogelcancer Of University Of Michigan Discusses Update Of KEYNOTE-189 Trial: Evaluated The Addition Of Pembrolizumab To Platinum…
Shirish Gadgeel MD @umrogelcancer Of University Of Michigan Discusses KEYNOTE-189 Roadmap: Long Term Data & Specific Biomarkers Will Continue To…
Shirish Gadgeel MD @umrogelcancer Of University Of Michigan Discusses KEYNOTE-189 Questions: Seen Benefit In PD-L1 0 Tumors, Further Follow Up…
… Qing Xu MD Of Shanghai Tenth Hospital Discusses Watson For Oncology (WFO): Developed With AI To Assist Oncologists In…
Qing Xu MD Of Shanghai Tenth Hospital Discusses Watson For Oncology (WFO): Developed With AI To Assist Oncologists In Treatment…
Toni Choureiri, MD, discusses the biomarker analyses from JAVELIN Renal 101. Background: The phase 3 JAVELIN Renal 101 trial in…
Tina Cascone MD Of The University of Texas MD Anderson Cancer Center Discusses Toxicity Of Nivolumab & Ipilimumab: Were Still…
Tina Cascone MD Of The University of Texas MD Anderson Cancer Center Discusses Results Of NEOSTAR Study: Study Looked At…
Dr. Kristin Higgins, MD, discusses the survival benefit of Durvalumab. Background: In the phase 3 PACIFIC study of patients with…
Vishwas Paralkar, PhD Of Cybrexa Therapeutics Discusses Why Is CBX-11 Data Significant: Our Platform Technology Is Specific & Only Delivers…
Vishwas Paralkar, PhD Of Cybrexa Therapeutics Discusses When Will CBX-11 Enter The Clinic: Clinical Program Starting In January Or February…
Vishwas Paralkar, PhD Of Cybrexa Therapeutics Discusses What Is Alphalex & How Does It Work: Makes Use Of Acidic Tumor…
Vishwas Paralkar, PhD Of Cybrexa Therapeutics Discusses Strategy Of Alphalex Developement: The Agnostic Nature Of The Platform Allows Us To…
Vishwas Paralkar, PhD Of Cybrexa Therapeutics Discusses How Is Alphalex Different: Its An Antigen Agnostic Tumor Targeting Technology, Can Target…
Vishwas Paralkar, PhD Of Cybrexa Therapeutics Discusses Cybrexa Additional Candidates: CBX-11 Is The First Of Many Candidates, More Data Will…
Dr. Sanjay Popat, PhD, dicusses Health-related quality of life results from ALTA-1. Background: Results from ALTA-1L (NCT02737501), an international, multicenter…
Dr. Kristin Higgins, MD, discusses how radiation was given in the PACIFIC trials. Background: In the phase 3 PACIFIC study…
Dr. Kristin Higgins, MD, disucsses the three-year overall survival update from the PACIFIC trial.Background: In the phase 3 PACIFIC study…
Michael R. Migden, M.D., discusses locally advanced cutaneous squamous cell carcinoms. Background: Cemiplimab (REGN2810) produced substantial antitumor activity with durable…
Michael R. Migden, M.D., discusses the phase 2 results of Cemiplimab. Background: Cemiplimab (REGN2810) produced substantial antitumor activity with durable…
Joel Neal MD Of Stanford University Medical Center Discusses Will Our Practice Change: As Of Now TAK-788 Is Not FDA…
Joel Neal MD Of Stanford University Medical Center Discusses What Is EGFR Exon 20 Insertion Mutant NSCLC: 15% Of Lung…
Joel Neal MD Of Stanford University Medical Center Discusses Results Of TAK-788 Trial: Among 28 Patients That Were Enrolled 43%…
Joel Neal MD Of Stanford University Medical Center Discusses Efficacy & Tolerance Of TAK-788: Patients Had Diarrhea, Nausea, Mild Rash,…
Karen Reckamp MD @KarenReckampMD Of City of Hope Discusses Who Should We Test: Theres No Screening Study That Has Been…
Karen Reckamp MD @KarenReckampMD Of City of Hope Discusses Lung Cancer On The Rise: Understanding Why People Are Getting Diagnosed…
Karen Reckamp MD @KarenReckampMD Of City of Hope Discusses Germline Mutations In Patients With Lung Cancer: Study Had 104 Patients…
Dr. Paul Paik, MD, discusses the future of Tepotinib. Background: MET exon 14 skipping (METex14) mutations – reported in 3~4%…
Dr. Paul K. Paik, MD, on the Phase II study of Tepotinib. Background: MET exon 14 skipping (METex14) mutations -…
Dr. Sanjay Popat discusses the quality of life for patients using Brigatinib. Background: Results from ALTA-1L (NCT02737501), an international, multicenter…
Dr. Michael Atkins MD Of Georgetown University Discusses Who Should Get Ipi:Nivo VS NIVO Monotherapy: Patients With Elevated LDH, BRAF…
Dr. Michael Atkins MD Of Georgetown University Discusses CHECKMATE-004 Trial Results: 57% Of Patients Were Alive At 4 Years, Treatment…
Dr. Sanjay Popat discusses if East Asian patients tolerate Brigatinib any differently than Crizotinb. Background: We report an analysis of…
Elad Sharon MD @EladSharonMD Of The National Cancer Institute Discusses Pembrolizumab Trial & Broadening Eligibility For HIV Patients: Patients With…
Nicholas Rohs MD @NickRohsMD Of Mount Sinai Discusses Combining Chemo & Immunotherapy Did Not Help Patients: Hope To See Survival…
Elizabeth R. Plimack MD MS @ERPlimackMD Of The Fox Chase Cancer Center Discusses Metastatic RCC Metastasectomy Study: Procedure Does Not…
Dr. Sanjay Popat, PhD, disucsses the Phase 3 ALTA-1L sub-analyses. Background: We report an analysis of BRG vs CRZ in…
Katja Weisel from University Medical Center Hamburg-Eppendorf discusses the role of daratumumab in first line treatment. Background: MM patients (pts)…
Katja Weisel from the University Medical Center Hamburg-Eppendorf discusses the efficacy and safety of daratumumab, bortezomib, and dexamethasone. Background: MM…
Armon Sharei PhD Of SQZ Biotech Discusses Trial Addressing HPV Positive Tumors: Enrolling Patients In Trial This Year, Looking At…
Background: MM patients (pts) with high cytogenetic risk have poor outcomes. In CASTOR, D-Vd prolonged progression-free survival (PFS) vs bortezomib…
Armon Sharei PhD Of SQZ Biotech Discusses SQZ Biotech: Engineer Multiple Facets Of Cell Function In A Very Practical Way,…
Armon Sharei PhD Of SQZ Biotech Discusses Questions About SQZ Biotech Technology: Use SQZ Platform To Deliver Antigens Directly Into…
Lee Schwartzberg MD @oncstatdoc Of West Cancer Center Discusses Prophylaxis For CINV: Patients Should Be Treated With A Triple Combination…
Lee Schwartzberg MD @oncstatdoc Of West Cancer Center Discusses Managing CINV: Developed New NK1 Receptor Antagonist, Clear Evidence Based Guidelines…
Lee Schwartzberg MD @oncstatdoc Of West Cancer Center Discusses Issues With CINV Remaining: If Guidelines Are Used Effectively A Large…
Lee Schwartzberg MD @oncstatdoc Of West Cancer Center Discusses Intravenous NEPA Study: Combination Therapy To Prevent CINV In Patients Receiving…
Lee Schwartzberg MD @oncstatdoc Of West Cancer Center Discusses Akynzeo: Convient & Flexible Dosing, Can Be Given Orally & Intravenously.…
Nicholas Rohs MD @NickRohsMD Of Mount Sinai Discusses Updates In Esophageal & Gastric Cancers: When Dose Of Xeloda & Oxaliplatin…
Nicholas Rohs MD @NickRohsMD Of Mount Sinai Discusses Lower Doses Of Xeloda & Oxaliplatin: Physicians Would Be Happy To Give…
Nicholas Rohs MD @NickRohsMD Of Mount Sinai Discusses Frontline KEYTRUDA In Gastroesophageal Cancer: Patients In Immunotherapy Arm Had Significantly Lower…
Danny Rischin MD Of Peter MacCallum Cancer Centre Discusses Who Should Get Monotherapy Or Pembrolizumab Combo: Reasonable To Use Pembrolizumab…
Danny Rischin MD Of Peter MacCallum Cancer Centre Discusses KEYNOTE-48 Trial: 882 Patients Were Enrolled In Under 2 Years, Primary…
Danny Rischin MD Of Peter MacCallum Cancer Centre Discusses KEYNOTE-48 Trial Implications: Will Provide An Opportunity For Patients To Have…
Anders Rabbe CEO Of Isofol Medical Discusses Phase 3 AGENT Study: Primary Endpoint Is Response Rate, Tumor Shrinkage, & PFS…
Anders Rabbe CEO Of Isofol Medical Discusses Arfolitixorin: Support From FDA, Doctors Are Excited About The Drug & How It…
Anders Rabbe CEO Of Isofol Medical Discusses Arfolitixorin: Increases Efficacy Of Standard Of Care Chemotherapy.
Alexis Peyroles MBA CEO Of OSE Immunotherapeutics Discusses TEDOPI: A Patented Combination Of 10 Neo-Epitopes. TEDOPI Is Being Evaluated In…
Alexis Peyroles MBA CEO Of OSE Immunotherapeutics Discusses TEDOPI Trials: NSCLC Trial Results In 2020, Primary Endpoint Is Overall Survival,…
Alexis Peyroles MBA CEO Of OSE Immunotherapeutics Discusses OSE Immunotherapeutics: French Company Based In Paris Focusing On How To Prolong…
Frederic Ors BS Of IMV, Inc. Discusses DeCidE1 study: Looking At Tumor Aggression After Treatment, Up To 30 Month Clinical…
Earn CME: https://naccme.com/program/7331 In this presentation from the ‘Looking to the Future With Hope: Advances in the Treatment of AML’…
Frederic Ors BS Of IMV, Inc. Discusses DeCidE1 study Questions: Why Not Use This Treatment In Earlier Stage Or Even…
Earn CME: https://naccme.com/program/7331 In this presentation from the ‘Looking to the Future With Hope: Advances in the Treatment of AML’…
Hannah Linden MD Of The University of Washington School of Medicine Discusses What We Specialize In: Multidisciplinary Approach, One Stop…
Hannah Linden MD Of The University of Washington School of Medicine Discusses Palbociclib & Alpelisib: Improved Survival Benefit In Younger…
Earn CME: https://naccme.com/program/7330 In this presentation from the ‘CLL in the Era of Targeted Therapy’ symposium at the 2019 Great…
Hannah Linden MD Of The University of Washington School of Medicine Discusses Hired Expert In Molecular Imaging: Huge Opportunity To…
Hannah Linden MD Of The University of Washington School of Medicine Discusses Estrogen Receptor Imaging: Specialty Diagnostic Test That Can…
Earn CME: https://naccme.com/program/7330 In this presentation from the ‘CLL in the Era of Targeted Therapy’ symposium at the 2019 Great…
Earn CME: https://naccme.com/program/7330 In this presentation from the ‘CLL in the Era of Targeted Therapy’ symposium at the 2019 Great…
Earn CME: https://naccme.com/program/7329 In this presentation from the ‘Minimal Residual Disease (MRD) Testing in Multiple Myeloma’ symposium at the 2019…
Earn CME: https://naccme.com/program/7329 In this presentation from the ‘Minimal Residual Disease (MRD) Testing in Multiple Myeloma’ symposium at the 2019…
Jakob Lindberg CEO Of Oncopeptides Discusses Melflufen Study: Lengthy Time To Next Treatment, Significant Reduction In Bone Pain, Positive Feedback…
Jakob Lindberg CEO Of Oncopeptides Discusses How Is Melflufen Different: Its A Lipophilic Peptide-Conjugated Alkylator That Rapidly Delivers A Highly…
Isaac Israel CEO @isaac2199 Of Kitov Pharmaceuticals Discusses Targeting CEACAM1: Idea Is To Block CEACAM Connections & Doing So Gives…
Isaac Israel CEO @isaac2199 Of Kitov Pharmaceuticals Discusses NT-219: First-In-Class, Novel Small Molecule Designed To Overcome Cancer Drug Resistance.
Isaac Israel CEO @isaac2199 Of Kitov Pharmaceuticals Discusses CM-24 Monoclonal Antibody: Plan To Initiate A Clinical Trial In Combination With…
Douglas S. Hawkins MD Of The University of Washington School of Medicine Discusses Questions About Larotrectinib: Who Should Be Tested,…
Douglas S. Hawkins MD Of The University of Washington School of Medicine Discusses Larotrectinib Efficacy & Safety In Pediatric TRK…
Douglas S. Hawkins MD Of The University of Washington School of Medicine Discusses How To Identify Patients With An NTRK…
Alexander Guminski MD Of The University of Sydney Discusses Where Is Cemiplimab Best Placed: Deploying Early As A Stand Alone…
Alexander Guminski MD Of The University of Sydney Discusses Phase 2 Study Of Cemiplimab: Response Rate Of 49 Estimated PFS…
Hossein Borghaei DO, MS @HosseinBorghaei Of Fox Chase Cancer Center discusses Pembrolizumab Survival Data: Minority Of Patients Are Surviving Beyond…
Hossein Borghaei DO, MS @HosseinBorghaei Of Fox Chase Cancer Center discusses Broadening Eligibility Criteria For Trials: A Lot Of Eligibility…
Daniel George MD @daniel_j_george Of Duke University Cancer Institute Discusses S-TRAC Study Data: Took 3 Years To Complete, Disease Free…
Daniel George MD @daniel_j_george Of Duke University Cancer Institute Discusses Disparity Associated With Our Patient Population: African Americans Make Up…
Daniel George MD @daniel_j_george Of Duke University Cancer Institute Discusses Adjuvant Therapy In RCC: Very Controversial But Needs Continual Development,…
Heather Cheng MD Of Seattle Cancer Care Alliance Discusses Molecular Tumor Boards: An Increasingly Needed Service, Implementing Molecular Tumor Boards…
Heather Cheng MD Of Seattle Cancer Care Alliance Discusses Molecular Tumor Boards In Clinical Practice: Increasingly Needed, GENTleMEN Study Offers…
Heather Cheng MD Of Seattle Cancer Care Alliance Discusses How To Help Men With BRCA1 & BRCA2 Mutations: Now Have…
Heather Cheng MD Of Seattle Cancer Care Alliance Discusses GENTleMEN Study: www.Gentlemen.org, Get A Saliva Kit Mailed To You &…
Heather Cheng MD Of Seattle Cancer Care Alliance Discusses Critical Importance Of Cascade Testing: Family Members Need Appropriate Counseling &…
Matthew Galsky, MD, Director of Genitourinary Medical Oncology At The Tisch Cancer Institute at Mount Sinai Discusses HCRN GU14-182: Randomized…
Matthew Galsky, MD, Director of Genitourinary Medical Oncology At The Tisch Cancer Institute at Mount Sinai Discusses HCRN GU14-182 Questions:…
Elizabeth Buchbinder MD Of DFCI Discusses SITC Advances In Cancer Immunotherapy: Great Opportunity For Clinicians To Learn About All The…
Elizabeth Buchbinder MD Of DFCI Discusses Mucosal Melanoma: Rare Form Of Melanoma With Much Lower Mutational Burden.
David Andorsky MD Of US Oncology Research Discusses MAGNIFY Study: Phase 3 Study Of Lenalidomide (Revlimid) Plus Rituximab (Rituxan) Followed…
David Anderson PhD Of VBI Vaccines Discusses VBI-1901 Vaccine: Two Different Components In The Vaccine gB & pp65 Delivered In…
David Anderson PhD Of VBI Vaccines Discusses Early Stages Of VBI-1901 Vaccine: Demonstrate Safety First, Encouraged By Correlations, Need To…
David Anderson PhD Of VBI Vaccines Discusses Are CMV antigens There: Multiple Publications Demonstrated Using A Variety Of Techniques That…
Omid Hamid MD @OmidHamidMD Of The Angeles Clinic Discusses ASCO 2019 Data: Many Approvals In Solid Tumors, Responses In Patients…
Omid Hamid MD @OmidHamidMD Of The Angeles Clinic Discusses First Line Melanoma Trial: Utilizes Microbiome Manipulation In Newly Diagnosed Patients…
Melissa Monak CPC Of Cleveland Clinic Discusses Cancer & Finances: Development Of A Financial Navigation Program To Ease The Burden…
Melissa Monak CPC Of Cleveland Clinic Discusses Financial Navigation Program: Studies Shown Better Outcomes With Patients In The Program.
Philippe Moreau, MD Of Nantes Faculty of Medicine Discusses Daratumumab Phase 3 Study: Could Be A Pivotal Study In The…
Philippe Moreau, MD Of Nantes Faculty of Medicine Discusses Daratumumab Phase 3 Study: Phase 3 Randomized Study Of Daratumumab +…
Kim Nguyen Chi MD Of The University Of British Colombia Discusses TITAN Study & Docetaxel: There Is Some Support To…
Kim Nguyen Chi MD Of The University Of British Colombia Discusses TITAN Study: Phase III Double-Blind, Randomized Study Of Apalutamide…
Guillermo Garcia-Manero, MD Of The MD Anderson Cancer Center Discusses Hypomethylating Agents In Myeloid Disorders: Lower Doses Of Decitabine And…
Dr. Luis Paz-Ares, MD, Phd of the Hospital Universitario 12 De Octubre gives a brief overview of his ASCO 2019…
Guillermo Garcia-Manero, MD Of The MD Anderson Cancer Center Discusses Should We Check If The Donor Has A Mutation: Depends…
Dr. Luiz Paz-Ares, MD, Phd of th Hospital Universitario 12 De Octubre gives a brief overview of his presentation from…
Jessica Geiger MD Of The Cleveland Clinic Discusses Are There Therapies For Squamous Cell Carcinoma: PD-1 Inhibitor Approved For Metastatic…
Jessica Geiger MD Of The Cleveland Clinic Discusses KEYNOTE-630: Randomizing Patients To Get Either Pembrolizumab Or Placebo.
Jessica Geiger MD Of The Cleveland Clinic Discusses Recruiting Patients For KEYNOTE-630: Looking For Patients With High Risk Features Like…
Alok Khorana, MD Of The Cleveland Clinic Discusses CASSINI Study Results: Reduction In Blood Clots When Taking Daily Rivaroxaban, No…
Josep Llovet, MD Of Mount Sinai School of Medicine Discusses Ramucirumab For Sorafenib Intolerant Patients With HCC: 8 Month Median…
Josep Llovet, MD Of Mount Sinai School of Medicine Discusses Ramucirumab Study: Good Safety Profile & Patients With Aggressive Tumors…
Josep Llovet, MD Of Mount Sinai School of Medicine Discusses When To Use Ramucirumab: Second Line & Aggressive Tumors, Moving…
Ali Mcbride PharmD @sheik2411 Of University of Arizona Cancer Center Discusses ACCC Educational Opportunities: Addressing Disease States Such As NSCLC,…
Ali Mcbride PharmD @sheik2411 Of University of Arizona Cancer Center Discusses Association Of Community Cancer Centers (ACCC): Over 2400 Members…
Ali Mcbride PharmD @sheik2411 Of University of Arizona Cancer Center Discusses What ACCC Achieves: Advocacy For Community Based Practice Sites…
Elizabeth R. Plimack MD MS @ERPlimackMD Of Fox Chase Cancer Center Discusses CARMENA Study: Looking At Cytoreductive Nephrectomy In Metastatic…
Elizabeth R. Plimack MD MS @ERPlimackMD Of Fox Chase Cancer Center Discusses KEYNOTE-426: Pembrolizumab Plus Axitinib VS Sunitinib For Advanced…
Alexa Schrock, PhD, of Foundation Medicine Discusses High Microsatellite Instability (MSI-H) in Colorectal Carcinoma Study: Tumor mutational burden is predictive…
Alexa Schrock PhD Of Foundation Medicine Discusses How To Act On TMB Score: Patients Might Need A Higher TMB To…
Bijal Shah MD Of Moffitt Cancer Center Discusses KTE-X19 Phase 1 Data: Arrived At a Cell Dose, Improved Safety Profile,…
Bijal Shah MD Of Moffitt Cancer Center Discusses KTE-X19 Study Safety: Median Age Is 46, No Impact Seen of Prior…
Dr. Celestia Higano, MD from the University of Washington discusses the PEACE III Trial Decreased Fracture Rate by Mandating Bone-protecting…
Dr. Celestia Higano, MD of the University of Washington discusses the Alliance A031201 a phase III trial of enzalutamide (ENZ)…
Neeraj Agarwal MD @neerajaiims Of Huntsman Cancer Institute Discusses Strength Of Talazoparib: Traps PARP On The DNA & Inhibits It…
Neeraj Agarwal MD @neerajaiims Of Huntsman Cancer Institute Discusses TALAPRO-2 Trial Patient Screening: No Need To Be Screened For Specific…
Dr. Celestia Higano, MD of the University of Washington discusses the Titan Trial Apalutamide vs Placebo During Androgen-Deprivation Therapy for…
Neeraj Agarwal MD @neerajaiims Of Huntsman Cancer Institute Discusses TALAPRO-2 Trial: Phase 3 Study Of Talazoparib (TALA) With Enzalutamide (ENZA)…
Neeraj Agarwal MD @neerajaiims Of Huntsman Cancer Institute Discusses Talazoparib + Enzalutamide Combo: Combination Is Safe & Works By Attacking…
Dr. Celestia Higano, MD of the University of Washington discusses the 10 year follow up of the Getug 16 Trial…
David M. Cognetti MD @KimmelCancerCtr Of Sidney Kimmel Cancer Center Discusses Photoimmunotherapy (PIT) Phase 2 Study Results: 30 Patients With…
David M. Cognetti MD @KimmelCancerCtr Of Sidney Kimmel Cancer Center Discusses Photoimmunotherapy (PIT) Phase 2 Study: Multicenter, Open-Label, Study Of…
David M. Cognetti MD @KimmelCancerCtr Of Sidney Kimmel Cancer Center Discusses Photoimmunotherapy (PIT) Phase 3 Study: Opening Now To Compare…
David M. Cognetti MD @KimmelCancerCtr Of Sidney Kimmel Cancer Center Discusses Photoimmunotherapy (PIT): Superior To Photodynamic Therapy Due To The…
David M. Cognetti MD @KimmelCancerCtr Of Sidney Kimmel Cancer Center Discusses Photoimmunotherapy Technology: Very Straight forward From A Technical Standpoint,…
Luis G. Paz-Ares, MD, Phd provides an overview of his presentation at ASCO 2019 entitled Efficacy and safety profile of…
Luis G. Paz-Ares, MD, Phd provides an overview of his presentation at ASCO 2019 entitled Efficacy and safety profile of…
Ahmad Tarhini Md, PhD of the Winship Cancer Center discusses the United States Intergroup E1609 A phase III randomized study…
Dr. Charles Craddock, MD discusses Graft V Host disease when combining Lenalidomide + Azacitidine
Charles Craddock MD PhD @charliecraddock of Queen Elizabeth Hospital discusses the Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in…
Marcus Butler, MD discusses TBI-1301-Effect of minimal lymphodepletion prior to ACT with TBI-1301, NY-ESO-1 specific gene-engineered TCR-T cells, on clinical…
Marcus Butler, MD of Princess Margaret Cancer Centre discusses the ILLUMINATE 301 A randomized phase 3 study of tilsotolimod in…
Philadelphia, PA (May 7, 2019) – Oncoceutics announced that the US Food and Drug Administration invited the company to present…
GRACE – Global Resource for Advancing Cancer Education Published on Feb 14, 2017 Dr. Luis Raez, MD FACP FCCP, Chief…
GRACE – Global Resource for Advancing Cancer Education Published on Dec 7, 2016 Spanish Lung Cancer Library: Antonio Calles, MD,…
GRACE – Global Resource for Advancing Cancer Education Published on Oct 25, 2016 Dr. Rafael Santana-Davila, Assistant Professor of Medicine…
GRACE – Global Resource for Advancing Cancer Education Published on Oct 25, 2016 Dr. Rafael Santana-Davila, Assistant Professor of Medicine…
GRACE – Global Resource for Advancing Cancer Education Published on Dec 28, 2016 Spanish Lung Cancer Library: Dr. Brian Hunis,…
GRACE – Global Resource for Advancing Cancer Education Published on Dec 12, 2016 Spanish Lung Cancer Library: Dr. Brian Hunis,…
GRACE – Global Resource for Advancing Cancer Education Published on Oct 14, 2015 Dr. Vivek Mehta, radiation oncologist, reviews the…
GRACE – Global Resource for Advancing Cancer Education Published on Dec 15, 2015 Drs. Ben Solomon, Leora Horn, & Jack…
GRACE – Global Resource for Advancing Cancer Education Published on Dec 5, 2018 Drs. H. Jack West, Medical Director -…
GRACE – Global Resource for Advancing Cancer Education Published on Jan 15, 2016 Terrie Schmith, a stage IV melanoma survivor,…
GRACE – Global Resource for Advancing Cancer Education Published on Jan 18, 2016 Dr. James Gulley, National Cancer Institute, discusses…
GRACE – Global Resource for Advancing Cancer Education Published on Jul 29, 2016 5th video in our series ASCO 2016…
GRACE – Global Resource for Advancing Cancer Education Published on Aug 23, 2017 Lung Cancer Video Library http://cancerGRACE.org/
GRACE – Global Resource for Advancing Cancer Education Published on Oct 14, 2018 Dr. Sandip Patel, Associate Professor of Medicine…
GRACE – Global Resource for Advancing Cancer Education Published on Apr 30, 2018 Dr. Vamsidhar Velcheti, Hematology and Medical Oncology…